ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 16

Monoclonal ACPA Promote Synovial Fibroblasts Migration Through a Peptidylarginine Deiminases (PAD) Dependent Pathway

Meng Sun1, Bence Rethi 1, Akilan Krishnamurthy 2, Vijay Joshua 3, Alexandra Circiumaru 1, Aase Hensvold 1, Marianne Engström 4, Sergiu-Bogdan Catrina 5, Johanna Steen 6, Vivianne Malmström 3, Caroline Grönwall 3, Lars Klareskog 7, Heidi Wähämaa 1 and Anca Catrina 7, 1Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, 2Rheumatology unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Solna, Stockholm, 3Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, 4Karolinska Institutet and Karolinska University Hospital, Stockholm, 5Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 6Stockholm University, Stockholm, 7Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-citrullinated protein/peptide antibodies (ACPA), Fibroblasts, Rheumatoid arthritis (RA), synovial cells, synovial fluid and monoclonal antibodies

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Cytokines & Cell Trafficking Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) play an important role in rheumatoid arthritis (RA) pathogenesis. ACPAs have different amino acid motif recognition patterns and show cross-reactivity to other protein modifications. We aimed to investigate the effect of different monoclonal ACPAs on RA synovial tissue derived fibroblast-like synoviocytes (FLS).

Methods: FLS were isolated from synovial tissue of RA patients by enzymatic digestion. ACPA and control monoclonal antibodies (mAbs) were derived from single B cells isolated from RA patients. Whole antibodies and F(ab’)2 fragments were tested in synovial fibroblast migration (IncuCyte live-cell analysis) and osteoclast formation assays. Blocking experiments were performed with soluble citrullinated proteins in SF migration. The role of mAbs cross-reactivity was tested in fibroblast migration assays using antibodies with distinct cross-reactivities, inhibitors of peptidylarginine deiminases (Cl-amidine and GSK199), histone acetyltransferase (anacardic acid) and histone deacetylase (trichostatin A). Binding patterns of monoclonal ACPAs were tested in synovial biopsies obtained from both healthy donors and RA patients. 

Results: Three monoclonal ACPAs (1325:01B09, 14T+:02D09 and14T+:02H12) enhanced fibroblast migration significantly compared to control mAb 1362:01E02-treated samples (mean±SD fold increase of 1.9±0.5, 1.7±0.4 and 1.8±0.6, respectively, p< 0.05), whereas the same antibodies showed no effect on osteoclast formation. Clone 1325:01B09 but neither 14T+:02D09 nor 14T+:02H12 is cross reactive with homo-citrullinated and acetylated targets (acetylated histone). The effect of 1325:01B09 on fibroblast migration was completely abolished by Cl-amidine or by pre-incubating the antibody with citrullinated fibrinogen or histone but not by citrullinated enolase or vimentin. Despite the cross-reactivity with acetylated epitopes, neither anacardic acid nor trichostatin A could modulate the 1325:01B09 effect on fibroblast migration. The fibroblast-promoting ACPA clone 1325:01B09 but not the osteoclastogenic 1325:04C03 co-localized with podoplanin-positive fibroblasts in the inflamed rheumatoid synovium. On the contrary to RA samples, healthy synovia were not stained by ACPAs. F(ab’)2 fragments of mAbs show similar effects on synovial fibroblast migration, osteoclast formation and a similar tissue binding pattern as the intact antibodies, indicating an Fc-independent mediated effect.

Conclusion: Some but not all ACPA clones could stimulate synovial fibroblast migration through a mechanism that was dependent on protein citrullination but no other protein modifications or FcR binding. Different clones acted on fibroblasts and osteoclasts suggesting unique pathological roles associated with individual ACPA specificities.


Disclosure: M. Sun, None; B. Rethi, None; A. Krishnamurthy, None; V. Joshua, None; A. Circiumaru, None; A. Hensvold, None; M. Engström, None; S. Catrina, None; J. Steen, None; V. Malmström, None; C. Grönwall, None; L. Klareskog, BMS, 2, Janssen, 2, Pfizer, 2; H. Wähämaa, None; A. Catrina, None.

To cite this abstract in AMA style:

Sun M, Rethi B, Krishnamurthy A, Joshua V, Circiumaru A, Hensvold A, Engström M, Catrina S, Steen J, Malmström V, Grönwall C, Klareskog L, Wähämaa H, Catrina A. Monoclonal ACPA Promote Synovial Fibroblasts Migration Through a Peptidylarginine Deiminases (PAD) Dependent Pathway [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/monoclonal-acpa-promote-synovial-fibroblasts-migration-through-a-peptidylarginine-deiminases-pad-dependent-pathway/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/monoclonal-acpa-promote-synovial-fibroblasts-migration-through-a-peptidylarginine-deiminases-pad-dependent-pathway/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology